Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 3,080 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Denali Therapeutics Stock Up 2.0 %

NASDAQ:DNLI opened at $21.26 on Monday. The firm’s fifty day simple moving average is $24.62 and its 200 day simple moving average is $24.88. The stock has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) EPS. On average, analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 654 shares during the period. Quest Partners LLC purchased a new stake in Denali Therapeutics in the third quarter worth about $73,000. Assetmark Inc. increased its stake in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $194,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DNLI has been the topic of a number of research reports. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Monday, December 16th. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a research note on Thursday, November 7th. Finally, Jefferies Financial Group raised their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.40.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.